Home Services In Country Services

In Country Services

In country  services

 

Synergy is focused on providing foreign pharmaceutical companies with the
services they need to successfully enter the U.S. market.  In effect, Synergy
serves as "in-country caretaker" for its foreign customers.  Synergy Research
can assist with regulatory affairs, clinical research including  pre-clinical through
regulatory approval, and creating a market presence in the United States.  
This concept has helped many startup firms secure funding to further the
R&D effort.

"By using Synergy Research as their local operations, Synergy Research's clients
will be able to create their own stable presence in the U.S. market with minimal
investment" explains Mario Guralnik, Chief Executive Officer, Synergy Research.
"We can help them meet the challenges of moving from a 'virtual' to a 'brick and
mortar' company with a presence in the United States."

Synergy Research's New Jersey facility provides an ideal location to the
pharmaceutical industry and Wall Street.  It also allows access to its employees'
broad range of skills, industry contacts, and experience in developing pharmaceutical and device products for foreign firms.

 

Synergy currently represents over 15 foreign device firms as their US Agent.  We also provide Medical Device Reporting Services under the latest guidlines and regulations, taking this huge burden over for virtual / foreign device manufactureres [21 CFR Part 803; MDR regulation section 519(a) of the FFD&C Act, amended by the Safe Medical Devices Act (SMDA) of 1990].

 

 

 

 

Synergy CRO Services

 

 

 

News & Events

  • GSK Receives EMEA Approval for Duodart LONDON (AP) - Pharmaceutical company GlaxoSmithKline... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
  • Proximagen Signs Deal With Upsher-Smith Proximagen Neuroscience plc, a biotechnology company... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • Mapping Technique Speeds Finding Specific Genes A Purdue University scientist was part of a... Read more>>
  • Key Protein Aids In DNA Repair Scientists have shown in multiple contexts that DNA damage ov... Read more>>
  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • FDA Says Additional Pixuvri Trial Needed, CTI Opens Drug to Expanded Access Cell Therapeutics... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>